Metabolic Epilepsies

Metabolic epilepsies are epilepsies in which a known or strongly suspected metabolic disorder contributes directly to the development of recurrent seizures. They are an internationally recognised aetiological category in the International League Against Epilepsy (ILAE) classification.

The term does not mean that every person with epilepsy has an abnormal metabolism, and it does not simply refer to a temporary seizure caused by low blood glucose, electrolyte disturbance or another acute illness. In a metabolic epilepsy, the underlying metabolic disorder is part of the enduring disease process that produces epilepsy.

What does “metabolic” mean?

Metabolism is the network of chemical reactions that allows cells to make energy, build and break down molecules, transport substances and maintain normal function. A defect in one of these pathways can alter the way the brain develops or functions and, in some disorders, make seizures a core feature.

The ILAE describes metabolic epilepsy as epilepsy that results directly from a known or presumed metabolic disorder. Examples can include disorders of energy production, vitamin-dependent pathways, amino-acid metabolism, transport across the blood–brain barrier and other biochemical systems.

Metabolic and genetic causes can overlap

Many metabolic disorders are caused by genetic variants. A person may therefore have an epilepsy that is both genetic and metabolic. These categories describe different aspects of cause: “genetic” describes the origin of the disorder, while “metabolic” describes the disease mechanism through which it affects the brain.

Not every metabolic epilepsy is inherited in the same way, and not every genetic epilepsy is metabolic.

Why recognising a metabolic epilepsy matters

Some metabolic epilepsies have treatments that target the underlying biochemical problem rather than only suppressing seizures. Reviews of treatable inherited metabolic epilepsies describe therapies ranging from specialist diets and vitamin supplementation to replacement of specific compounds and other pathway-directed treatments.

For some conditions, treatment is most effective when started early. This means that identifying the underlying disorder can influence seizure control, development, movement symptoms, nutrition, monitoring and counselling for the person and their family.

Examples of metabolic epilepsies

Metabolic epilepsy is not one disease. The group contains many rare disorders with very different mechanisms.

GLUT1 deficiency syndrome

Read the full guide: GLUT1 Deficiency Syndrome and Epilepsy →

Glucose transporter type 1 deficiency syndrome is usually caused by pathogenic variants in SLC2A1. The GLUT1 transporter is responsible for moving glucose across the blood–brain barrier. When transport is impaired, the brain has less access to glucose as an energy source.

Epilepsy can occur alongside movement disorders, developmental difficulties, acquired microcephaly or exercise-related symptoms, although the phenotype is highly variable. Ketogenic dietary therapy provides ketone bodies as an alternative brain fuel and is an established disease-specific treatment.

Pyridoxine-dependent epilepsy due to ALDH7A1 deficiency

Read the full guide: Pyridoxine-Dependent Epilepsy (ALDH7A1) →

Pyridoxine-dependent epilepsy associated with ALDH7A1 is a disorder of lysine metabolism. Seizures often begin very early in life and can respond dramatically to pharmacological doses of pyridoxine, or vitamin B6.

International consensus guidance also describes lysine-reduction therapies, including lysine restriction and arginine supplementation, as additional approaches intended to reduce the accumulation of harmful metabolites. Management requires specialist metabolic and neurological supervision.

Disorders of brain energy metabolism

Pyruvate Dehydrogenase Complex Deficiency and Epilepsy →
Mitochondrial Epilepsy →

Other metabolic epilepsies can arise when the brain cannot produce or use energy normally. Examples include pyruvate dehydrogenase deficiency and some mitochondrial disorders. Ketogenic dietary therapy has a specific role in some energy-metabolism disorders, but it is not appropriate for every metabolic disease.

Other treatable metabolic disorders

The wider group includes disorders involving vitamins and cofactors, amino acids, creatine metabolism, folate pathways and other biochemical systems. Because the treatment for one disorder may be ineffective or unsafe in another, metabolic therapy should be based on a defined or strongly suspected diagnosis rather than tried as a general epilepsy remedy.

How metabolic epilepsy can present

There is no single seizure type that identifies a metabolic cause. Clues can include seizures beginning in the neonatal period or infancy, developmental delay or regression, movement disorders, abnormal muscle tone, episodic worsening with fasting or illness, unexplained metabolic abnormalities, involvement of other organs, or a family history suggesting an inherited disorder.

However, some people have much milder or later-presenting forms. The absence of severe developmental disability does not automatically exclude a metabolic diagnosis.

Metabolic epilepsy is different from an acute symptomatic seizure

A person without epilepsy can have a seizure during a severe temporary metabolic disturbance such as profound hypoglycaemia, hyponatraemia or another acute systemic problem. That event may be classified as an acute symptomatic seizure rather than epilepsy if the seizure occurs because of the temporary disturbance and there is no enduring predisposition to recurrent unprovoked seizures.

By contrast, a metabolic epilepsy reflects a continuing disorder that makes recurrent seizures part of the underlying condition.

How the diagnosis is investigated

Investigation depends on the age, seizure pattern and accompanying features. It may include blood and urine biochemical tests, cerebrospinal-fluid studies, EEG, MRI, targeted metabolic assays and genetic testing. Increasingly, genomic testing can identify a metabolic disorder even when the biochemical presentation is incomplete or atypical.

A diagnosis is not made from one abnormal laboratory value alone. Results have to be interpreted in the clinical context, and some tests are highly sensitive to timing, fasting state, illness, diet, medication or sample handling.

Why ordinary antiseizure medicines may not be enough

Antiseizure medicines can still be important, but they may treat the seizures without correcting the underlying metabolic problem. In some disorders, a targeted therapy can produce substantially better seizure control or protect development. In others, treatment remains mainly symptomatic.

This is why a diagnosis such as “drug-resistant epilepsy” should not end the search for an underlying cause when the history suggests a potentially treatable metabolic disorder.

Worldwide access is unequal

Recognition of rare metabolic epilepsies depends on access to trained clinicians, biochemical laboratories, genetic testing, specialist dietetic services and reliable supplies of medicines or medical foods. Those resources are distributed unevenly around the world.

WHO reports major global inequalities in epilepsy diagnosis and treatment more broadly, with most people with epilepsy living in low- and middle-income countries and substantial gaps in access to neurological care, medicines and diagnostic technologies. For rare metabolic epilepsies, the additional need for specialised testing can widen that gap further.

The central point

Metabolic epilepsy is not a single seizure syndrome and it is not synonymous with a temporary metabolic trigger. It describes epilepsy caused by an underlying metabolic disorder. Finding that cause can matter because some of these disorders have highly specific treatments that go beyond conventional antiseizure medication.

Additional metabolic epilepsy

Lysosomal Storage Disorders and Epilepsy →

Sources

Medical note: metabolic epilepsies require individual specialist assessment. Vitamins, restrictive diets and metabolic supplements can cause harm when used inappropriately and should not be started as a general treatment for unexplained seizures.

Evidence checked: September 2026.